SCHEMBL3695035

SCHEMBL3695035

Cc1cc(C)n2nc(NC(=O)Cc3ccc(F)cc3)c(-c3ccccc3)c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 3/20 0.55
KCNQ2 O43526 3/20 0.55
MAPK14 Q16539 2/20 0.51
KDM4E B2RXH2 4/20 0.49
KMT2A Q03164 3/20 0.49
POLB P06746 2/20 0.49
MEN1 O00255 2/20 0.49
ALDH1A1 P00352 4/20 0.46
PTGS2 P35354 1/20 0.45
HTR6 P50406 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
ATM Q13315 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
APOBEC3A P31941 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3708798 0.86 KCNQ3 (0.56) KCNQ3KCNQ2MAPK14KDM4EKMT2A
SCHEMBL3705325 0.81 KCNQ3 (0.54) KCNQ3KCNQ2KDM4EKMT2APOLB
SCHEMBL3701966 0.80 KCNQ3 (0.56) KCNQ3KCNQ2KDM4EKMT2APOLB
SCHEMBL3701916 0.79 MAPK14 (0.52) KCNQ3KCNQ2MAPK14KMT2AALDH1A1
SCHEMBL3704938 0.77 KCNQ3 (0.74) KCNQ3KCNQ2KDM4EKMT2APOLB
SCHEMBL3707258 0.77 MAPK14 (0.48) KCNQ3KCNQ2MAPK14KMT2AMEN1
SCHEMBL3702142 0.77 KCNQ3 (0.76) KCNQ3KCNQ2KDM4EKMT2APOLB
SCHEMBL3706186 0.76 KCNQ3 (0.57) KCNQ3KCNQ2KDM4EKMT2AMEN1
SCHEMBL3702148 0.75 KCNQ3 (0.52) KCNQ3KCNQ2KDM4EKMT2APOLB
SCHEMBL3706811 0.75 MAPT (0.43) KCNQ3KCNQ2MAPK14KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US claimed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO claimed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US claimed
US-8609669-B2 Potassium channel modulators ABBVIE INC. (US) 2013-12-17 US disclosed
WO-2012067822-A1 PYRAZOLO [1, 5 -A] PYRIMIDIN POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122888-A1 Potassium Channel Modulators ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122888-A1 Potassium Channel Modulators KCNQ1, KCNQ2, KCNJ2 KCNQ3 4/4885KCNQ2 2/4885MAPK14 3073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.